ArticleMedical oncology (Northwood, London, England)2014
Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Pooled it
- XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.Signal transduction and targeted therapy · 2024Trial
- VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunity.bioRxiv : the preprint server for biology · 2025Article
- Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for Cold-to-Hot tumor transformation.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.Molecular cancer · 2024Review
- Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma.Clinical and translational medicine · 2024Article
- Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.Frontiers in immunology · 2024Review
- Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing.BMC immunology · 2023Article
- Lung cancer immunotherapy: progress, pitfalls, and promises.Molecular cancer · 2023Review
- Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity.Seminars in cancer biology · 2022Review
- Direct and indirect regulation of the tumor immune microenvironment by VEGF.Journal of leukocyte biology · 2022Review
- Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.Archives of pharmacal research · 2022Review
- VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.International journal of biological sciences · 2022Review
- The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer.Frontiers in immunology · 2021Review
- Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.Journal of clinical medicine · 2020Review
- New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.Journal of cancer research and clinical oncology · 2020Review
- A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Frontiers in immunology · 2020Review
- Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15.Journal for immunotherapy of cancer · 2019Article
- Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine-induced killer cells (CIK cells) are a heterogeneous population of cells generated from peripheral blood mononuclear cells, which share phenotypic and functional properties with both natural killer and T cells. CIK cells therapy, as an adoptive immunotherapy with strong antitumor activity in vitro, represents a promising approach for the treatment of a broad array of malignant tumors. However, clinical trials in CIK cells therapy did not show more noticeable improvement as anticipated in cure rates or long-term survival. Possible explanations are that abnormal tumor vasculature and hypoxic microenvironment may highly limit the therapeutic benefits of CIK cells therapy. We hypothesized that antiangiogenesis therapy could enhance the antitumor efficacy of CIK cells by normalizing tumor vasculature and modulating tumor hypoxic microenvironment. In this study, we combined bevacizumab and adoptive CIK cells therapy in the treatment of lung adenocarcinoma bearing murine models. Flow cytometry, intravital microscopy and immunohistochemistry were applied to detect tumor vasculature and hypoxic microenvironment as well as the infiltration of CIK cells. The results indicated that bevacizumab-combined adoptive CIK cells had synergistic inhibition effects on the growth of lung adenocarcinoma. Hypoxia significantly inhibited the infiltration of CIK cells into tumor tissue. Bevacizumab could normalize tumor vasculature and decrease tumor hypoxic area. Furthermore, combination therapy enhanced more CIK cells infiltrated into tumor compared with other treatment. Bevacizumab improves antitumor efficacy of CIK cells transfer therapy in non-small cell lung cancer (NSCLC). The study provides a reasonable and beneficial strategy that combined antiangiogenesis therapy with CIK cells therapy for patients of advanced stage non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.